# Final Report: Idea 75

## Final ELO Score: 1214.8

## Final Hypothesis

**Title**: ROS-Responsive Microparticle-Embedded DnaE2 Inhibitors for Pulmonary Co-Delivery with Rifampicin

**Key Idea**: Thioketal-caged DnaE2 blockers formulated into inhaled PLGA microparticles release drug in oxidative phagosomes, suppressing mutagenesis during rifampicin therapy.

**Paragraph**: Inhalation places inhibitors directly at pulmonary lesions and synchronises exposure with rifampicin, limiting systemic ROS exposure.

**Approach**: Spray-dry PLGA particles (3 µm MMAD); ROS-triggered release; hollow-fibre rifampicin combo; murine aerosol infection relapse.

**Key References**: Boshoff 2003; Cirz 2007; Amara 2019; NEW—Liang et al., Adv. Drug Deliv. Rev., 2021 (ROS-cleavable PLGA) [Liang 2021].  
Modifications: Added inhaled PLGA formulation, harmonising spatial and temporal delivery.

────────────────────────────────────────────────────────
IDEA 40  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

ROS-Responsive Microparticle-Embedded DnaE2 Inhibitors for Pulmonary Co-Delivery with Rifampicin

### Key Idea

Thioketal-caged DnaE2 blockers formulated into inhaled PLGA microparticles release drug in oxidative phagosomes, suppressing mutagenesis during rifampicin therapy.

### Detailed Explanation

Inhalation places inhibitors directly at pulmonary lesions and synchronises exposure with rifampicin, limiting systemic ROS exposure.

### Implementation Approach

Spray-dry PLGA particles (3 µm MMAD); ROS-triggered release; hollow-fibre rifampicin combo; murine aerosol infection relapse.

### Key References

Boshoff 2003; Cirz 2007; Amara 2019; NEW—Liang et al., Adv. Drug Deliv. Rev., 2021 (ROS-cleavable PLGA) [Liang 2021].  
Modifications: Added inhaled PLGA formulation, harmonising spatial and temporal delivery.

────────────────────────────────────────────────────────
IDEA 40  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1214.8



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1214.8



## Citations

- Liang 2021
